herobanner-psa

Imagine Small Moments With Psoriatic Arthritis Symptom Relief

XELJANZ* is used to treat adults with active psoriatic arthritis when 1 or more TNF blocker medicines have been used, and did not work well or cannot be tolerated.

*Taken with a nonbiologic DMARD like methotrexate.

Results From PsA Clinical Trials Prove XELJANZ Can:

Help reduce joint pain
Help reduce joint swelling
Help improve physical function

In some PsA patients, XELJANZ can help improve skin symptoms

Not approved for plaque psoriasis.

In some patients, XELJANZ can reduce joint pain and swelling of active psoriatic arthritis in as early as 2 weeks§

§For others it could take up to three months or longer. Individual results may vary.

Adult patients with active PsA were evaluated in clinical trials. Patients in the clinical studies were taking background medicines such as methotrexate. One study evaluated patients when another medicine such as methotrexate did not work well or could not be tolerated. A second study evaluated patients when medicines called TNF blockers did not work well or could not be tolerated. XELJANZ is approved for use in patients when TNF blockers did not work well or could not be tolerated.

Explore Clinical Trial Results

Working With Your Doctor

If your current treatment isn’t working well enough to manage your PsA symptoms, it’s important to have an open and honest discussion with your doctor. Every appointment is an opportunity to improve the dialogue with your doctor and discuss how to manage your PsA. If XELJANZ is appropriate for you and you want to continue with Pfizer's savings and support, make sure to ask your doctor to stay on brand-name XELJANZ.

Prepare

Before your next appointment, get ready for the conversation by reflecting on your current treatment plan and tracking your recent symptoms. The information could be helpful in finding a treatment plan that may work best for you.

Share

It may help make it easier to talk about if you write down any questions or concerns you may have ahead of your appointment to give your doctor a complete picture of your situation.

Align

Communicate your treatment goals with your healthcare team. Help them understand your hopes, fears, and expectations. This conversation will be useful in getting everyone on the same page.

View Doctor Discussion Guide

Savings & Support

Are you starting on treatment with XELJANZ for PsA, but you’re concerned about covering the cost? You may be eligible for the XELJANZ Co-Pay Savings Program for commercially insured patients or qualify for other financial support resources to help you access your treatment. Terms and conditions and eligibility requirements apply.

Pay as little as $0 per month for your XELJANZ prescription

Eligibility required. May have annual savings up to $4,000-$15,000 depending on insurance.
Federal and state healthcare beneficiaries ineligible. No membership fee. Offer not valid
for cash paying patients. Terms and conditions apply.

XELJANZ Co-Pay XELJANZ (tofacitinib) co-pay savings card

If you are unable to confirm your eligibility or have additional questions, call XELSOURCE at 1-844-935-5269.

For eligible underinsured or uninsured patients, XELSOURCE may offer financial assistance through the Pfizer Patient Assistance Program. Call XELSOURCE to learn more about these programs. Terms and conditions/eligibility requirements apply.

Sign Up Now

XELJANZ (tofacitinib) 5mg prescription bottle

Easy-To-Open Bottle

The easy-to-open XELJANZ bottle cap has received an Arthritis Foundation Ease-of-Use Commendation.

The Arthritis Foundation's Ease of Use Commendation recognizes products, such as the XELJANZ bottle cap, which are intended to make certain tasks easier for people who have arthritis and other physical limitations.

Learn more at arthritis.org.

This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.